These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 31050739)
1. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. Castain L; Perrier M; Charpentier C; Palich R; Desire N; Wirden M; Descamps D; Sayon S; Landman R; Valantin MA; Joly V; Peytavin G; Yazdanpanah Y; Katlama C; Calvez V; Marcelin AG; Todesco E J Antimicrob Chemother; 2019 Jul; 74(7):2019-2023. PubMed ID: 31050739 [TBL] [Abstract][Full Text] [Related]
2. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. Perrier M; Castain L; Regad L; Todesco E; Landman R; Visseaux B; Yazdanpanah Y; Rodriguez C; Joly V; Calvez V; Marcelin AG; Descamps D; Charpentier C J Antimicrob Chemother; 2019 Jun; 74(6):1679-1692. PubMed ID: 30768160 [TBL] [Abstract][Full Text] [Related]
3. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. Perrier M; Visseaux B; Landman R; Joly V; Todesco E; Yazdanpanah Y; Calvez V; Marcelin AG; Descamps D; Charpentier C J Antimicrob Chemother; 2018 Jan; 73(1):173-176. PubMed ID: 29077926 [TBL] [Abstract][Full Text] [Related]
4. Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors. Manasa J; Varghese V; Pond SLK; Rhee SY; Tzou PL; Fessel WJ; Jang KS; White E; Rögnvaldsson T; Katzenstein DA; Shafer RW Sci Rep; 2017 Sep; 7(1):11559. PubMed ID: 28912582 [TBL] [Abstract][Full Text] [Related]
5. HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy. Blanch-Lombarte O; Santos JR; Peña R; Jiménez-Moyano E; Clotet B; Paredes R; Prado JG J Antimicrob Chemother; 2020 Sep; 75(9):2535-2546. PubMed ID: 32556165 [TBL] [Abstract][Full Text] [Related]
6. Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya. Coetzer M; Ledingham L; Diero L; Kemboi E; Orido M; Kantor R J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29098809 [TBL] [Abstract][Full Text] [Related]
7. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy. Lambert-Niclot S; Flandre P; Valantin MA; Peytavin G; Sayon S; Morand-Joubert L; Delaugerre C; Algarte-Genin M; Katlama C; Calvez V; Marcelin AG J Antimicrob Chemother; 2012 Jun; 67(6):1470-4. PubMed ID: 22396434 [TBL] [Abstract][Full Text] [Related]
8. Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients. Teto G; Nka AD; Fokam J; Bouba Y; Takou D; Fabeni L; Carioti L; Armenia D; Semengue ENJ; Dambaya B; Sosso SM; Colizzi V; Perno CF; Ceccherini-Silberstein F; Santoro MM; Ndjolo A Sci Rep; 2022 Jan; 12(1):1374. PubMed ID: 35082353 [TBL] [Abstract][Full Text] [Related]